Navigation Links
New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
Date:12/12/2007

is

In the U.S. study, rates of discontinuation due to AEs for the placebo, desvenlafaxine 50 mg/day and desvenlafaxine 100 mg/day groups were 3 percent, 3 percent and 7 percent, respectively. In the international study, these rates for the placebo, desvenlafaxine 50 mg/day and desvenlafaxine 100 mg/day groups were 3 percent, 5 percent and 7 percent, respectively.

Adverse events in both of these studies that were reported by at least five percent of the subjects and twice the rate of placebo included asthenia, anorexia, anxiety, dizziness and insomnia. Events also reported by at least five percent of the subjects and twice the rate of placebo in the international study were nausea, somnolence and abnormal ejaculation; and in the U.S. study they were constipation, dry mouth, myalgia, impotence and sweating. In the U.S. study, nausea was not among the adverse events reported by at least five percent of the subjects and twice the rate of placebo.

A PDF version of the poster presentation of this data will be available on Wyeth's website, http://www.Wyeth.com, shortly after it is presented today, beginning at 5:30 p.m., Eastern U.S. Time.

"Major depressive disorder is a chronic and disabling disease that can cause significant distress and impair an individual's daily functioning," says Michael Liebowitz, M.D., lead author of the poster and a professor of clinical psychiatry. "Unfortunately, research and clinical practice suggest that a large percentage of patients with major depression do not respond to initial antidepressant therapy, leaving these patients still struggling with symptoms of depression. Clearly, there is a need for additional treatment options."

Desvenlafaxine was discovered and developed by Wyeth Research. As a leader in neuroscience, the Company is committed to discovering and developing a broad range of treatments for mental illness.

About Antidepressants

A
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)...  MiMedx Group, Inc. (NASDAQ: MDXG ), ... regenerative biomaterials and bioimplants processed from human amniotic membrane, ... of credit with Bank of America.  The revolving line ... accounts receivable and inventory, allows MiMedx to borrow up ... will be used for general corporate purposes. ...
(Date:5/20/2013)...  (PSHR) Pacific Shore Holdings, Inc. a consumer ... broad range of product categories lines, today reports ... BlueWater Advisory Group, to provide strategic counsel and ... to direct the company,s outreach and investor awareness ... Matthew Mills , Pacific Shore Holdings, president ...
(Date:5/20/2013)... Biomarkers and Clinigene International are set to unveil their ... 2013 AAPS/ National Biotechnology Conference May 20-22 ... Marina , San Diego, CA. ... company representatives at their collaborative seminar, "Biosimilarity, Immunogenicity and ... 1-2 p.m. in the conference,s Spinnaker Room. ...
(Date:5/20/2013)... Md. and BALTIMORE , May 20, ... a regional private-public partnership focusing on commercializing market-relevant ... in Central Maryland , today ... as the first Entrepreneur-in-Residence (EIR) for BHI at ... Heart, Lung and Blood Institute (NHLBI). Dr. ...
Breaking Biology Technology:Pacific Shore Holdings Retains Investor Relations Firm 2Pacific Biomarkers and Clinigene International To Announce Laboratory Solutions for Developers of Biosimilars at 2013 AAPS/ National Biotechnology Conference 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 3BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 4
... Signalife, Inc.,(Amex: SGN ) has announced its ... and Electrophysiology to be held December 2-6, 2007 ... who has been testing,Signalife,s wireless Fidelity 400 Intracardiac ... Heart Center, will,present a prototoype of the Fidelity ...
... 3 Immtech Pharmaceuticals,Inc. (Amex: IMM ) announced ... (BMO) Capital Markets Focus on Healthcare Conference. On Tuesday,December ... to present,in the Biotechnology Room 4.04 -- the Millennium ... About Immtech Pharmaceuticals, Inc., Immtech Pharmaceuticals, Inc. ...
... & Diet" (p. 54). The latest chapter,of Newsweek,s "Health ... foods impact the odds of getting pregnant. Harvard University,researchers ... Patrick,J. Skerrett, authors of the new book "The Fertility ... play in conception and weigh in on,their surprising findings. ...
Cached Biology Technology:Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology 2Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology 3Immtech to Present at The Bank of Montreal Healthcare Conference 2NEWSWEEK: Media Lead Sheet/December 10, 2007 Issue (on newsstands Monday, December 3). 2NEWSWEEK: Media Lead Sheet/December 10, 2007 Issue (on newsstands Monday, December 3). 3NEWSWEEK: Media Lead Sheet/December 10, 2007 Issue (on newsstands Monday, December 3). 4NEWSWEEK: Media Lead Sheet/December 10, 2007 Issue (on newsstands Monday, December 3). 5
(Date:5/21/2013)... and health stores, phosphatidylserine is a natural food ... to improve cognition and slow memory loss, it,s ... impairment. Now a team headed by Prof. Gil ... University,s Department of Human Molecular Genetics ... functioning of genes involved in degenerative brain disorders, ...
(Date:5/21/2013)... scientists have developed many devices that can reopen clogged ... effective, each of these treatments has drawbacks, including the ... MIT analyzes the potential usefulness of a new treatment ... stents, but may pose fewer risks. With this new ... only a brief period, during which it releases a ...
(Date:5/21/2013)... genes function without changing the underlying DNA sequence, ... pregnant women during any trimester, potentially providing a ... after giving birth, and an opportunity to intervene ... the small study involving 52 pregnant women are ... . , "Postpartum depression can be harmful to ...
Breaking Biology News(10 mins):Common food supplement fights degenerative brain disorders 2Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3
... researchers have identified a key regulator that controls the speed ... the function of this regulator, animals sped up their rate ... The U of A research team, led by molecular ... they were studying, DHR4: The protein acted as a sentinel ...
... SCOTTSDALE, Ariz. Sept. 28, 2011 ... award from the Arizona BioIndustry Association (AZBio) for ... TD2, a subsidiary of the Translational Genomics Research ... to biopharmaceutical companies using cutting-edge technology to minimize ...
... the U.S. Department of Energy,s Savannah River National Laboratory ... led to a special issue of the Health ... in the Chernobyl Exclusion Zone 25 Years After ... auspices of the DOE Office of Environmental Management,s (EM) ...
Cached Biology News:TGen Drug Development recognized for economic development of Arizona biosciences 2Journal focuses on Savannah River National Labratory, Chernobyl Laboratory collaboration 2Journal focuses on Savannah River National Labratory, Chernobyl Laboratory collaboration 3